selected scholarly activity
-
academic article
-
Quality of
end‐of‐life care in multiple myeloma: A13‐year analysis of a population‐based cohort in Ontario, Canada. British Journal of Haematology. 199:688-695. 2022 - Teclistamab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine. 387:1721-1723. 2022
- Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) Database. eJHaem. 3:1252-1261. 2022
- What do hematology residents know about caring for older adults with cancer? A national survey of Canadian hematology residents' knowledge and interests. Journal of Geriatric Oncology. 13:1236-1240. 2022
- Real‐world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database. Cancer Medicine. 2022
- Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies. JCO Global Oncology. 8:e2200119. 2022
- OAB-042: The impact of marginalization on treatment receipt and overall survival in newly diagnosed multiple myeloma patients in Ontario: a population-based cohort study. Clinical Lymphoma, Myeloma and Leukemia. 22:S25-S26. 2022
- P-136: Global myeloma trial participation and drug access in the era of novel therapies. Clinical Lymphoma, Myeloma and Leukemia. 22:S110-S110. 2022
- P-191: The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: a systematic review. Clinical Lymphoma, Myeloma and Leukemia. 22:S140-S140. 2022
- P-201: Outcomes of transplant-ineligible myeloma patients using bortezomib/lenalidomidecontaining regimens in the real world: a report from the Canadian Myeloma Research Group Database. Clinical Lymphoma, Myeloma and Leukemia. 22:S145-S146. 2022
- P-261: Treatment attrition rates in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis. Clinical Lymphoma, Myeloma and Leukemia. 22:S180-S181. 2022
- Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database. Clinical Lymphoma, Myeloma and Leukemia. 22:608-617. 2022
- Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. Blood Advances. 6:3991-3995. 2022
- Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database. British Journal of Haematology. 198:93-102. 2022
- Gender disparities in multiple myeloma publications.. Journal of Clinical Oncology. 40:e23000-e23000. 2022
- Quality of end-of-life care for patients with multiple myeloma: A 12-year analysis of a population-based cohort.. Journal of Clinical Oncology. 40:12031-12031. 2022
- Financial toxicity in hematological malignancies: a systematic review. Blood Cancer Journal. 12:74. 2022
- Just the facts: how to diagnose and manage patients with multiple myeloma in the emergency department?. Canadian Journal of Emergency Medicine. 24:256-258. 2022
- Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database. Current Oncology. 29:1575-1582. 2022
- A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients. Bone Marrow Transplantation. 57:295-298. 2022
- Patient-reported outcome measures are associated with health care utilization in patients with transplant ineligible multiple myeloma: a population-based study. Blood Cancer Journal. 12:17. 2022
- Daratumumab in newly diagnosed MM — incorporating lessons learnt from CASSIOPEIA, MAIA and beyond. Nature Reviews Clinical Oncology. 19:3-4. 2022
- Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis. Frontiers in Oncology. 12:826342. 2022
- Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. Bone Marrow Transplantation. 57:31-37. 2022
- Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care: Recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research Network) Consensus Guideline Consortium. Clinical Lymphoma, Myeloma and Leukemia. 22:e41-e56. 2022
- Cardiovascular events among recipients of hematopoietic stem cell transplantation. European Heart Journal. 42:ehab724.2876. 2021
- P-222: Extended follow-up safety and efficacy results of Belantamab mafodotin (Belamaf) 1.92 mg/kg or 2.5 mg/kg combined with POM and DEX for the treatment of relapsed/refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia. 21:S162-S162. 2021
- Trajectory of Symptoms in Patients Undergoing Autologous Stem Cell Transplant for Multiple Myeloma: A Population-Based Cohort Study of Patient-Reported Outcomes. Clinical Lymphoma, Myeloma and Leukemia. 21:e714-e721. 2021
- Symptom burden in transplant-ineligible patients with newly diagnosed multiple myeloma: a population-based cohort study. Haematologica. 106:1991-1994. 2021
- External validation of the FIRST trial’s simplified frailty score in a population-based cohort. Leukemia. 35:1823-1827. 2021
- Disparities in treatment patterns and outcomes among younger and older adults with newly diagnosed multiple myeloma: A population-based study. Journal of Geriatric Oncology. 12:508-514. 2021
- Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the “real world”. Annals of Hematology. 100:1261-1266. 2021
- Transplant-ineligible newly diagnosed multiple myeloma: Current and future approaches to clinical care: A Young International Society of Geriatric Oncology Review Paper. Journal of Geriatric Oncology. 12:499-507. 2021
- Burden of Treatment Among Older Adults With Newly Diagnosed Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia. 21:e152-e159. 2021
- Efficacy of Daratumumab Containing Regimens Post Lenalidomide Maintenance in Transplant Eligible Patients: Real-World Experience from the Canadian Myeloma Research Group Database. Blood. 136:26-27. 2020
- Novel Single Panel Method for Minimal Residual Disease Detection for Plasma Cells By Flow Cytometry. Blood. 136:6-7. 2020
- Symptom Burden in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Population-Based Study of Patient-Reported Outcomes. Blood. 136:30-31. 2020
- Trajectory of Symptoms after Autologous Stem Cell Transplant Among Patients with Multiple Myeloma: A Population-Based Study. Blood. 136:1-2. 2020
- Geriatric assessment and quality of life changes in older adults with newly diagnosed multiple myeloma undergoing treatment. Journal of Geriatric Oncology. 11:1279-1284. 2020
- Maintenance therapy in transplant ineligible adults with newly‐diagnosed multiple myeloma: A systematic review and meta‐analysis. European Journal of Haematology. 105:626-634. 2020
- Caring for older patients with cancer during the COVID-19 pandemic: A Young International Society of Geriatric Oncology (SIOG) global perspective. Journal of Geriatric Oncology. 11:1175-1181. 2020
- Registry Data and Conditioning Therapy for Allogeneic Hematopoietic Cell Transplant and Lymphoma. JAMA Oncology. 6:989-989. 2020
- Simplified frailty assessment tools: are we really capturing frailty or something else?. Leukemia. 34:1967-1969. 2020
- Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma. Journal of Geriatric Oncology. 11:764-768. 2020
- Perspectives from the Cancer and Aging Research Group: Caring for the vulnerable older patient with cancer and their caregivers during the COVID-19 crisis in the United States. Journal of Geriatric Oncology. 11:753-760. 2020
- Geriatric hematology research at the 2019 American Society of Hematology annual meeting: Young International Society of geriatric oncology perspective paper. Journal of Geriatric Oncology. 11:735-739. 2020
- Arti Hurria and the progress in integrating the geriatric assessment into oncology: Young International Society of Geriatric Oncology review paper. Journal of Geriatric Oncology. 11:203-211. 2020
- Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia. 20:98-104.e1. 2020
- The Evolving Field of Bone Imaging in Multiple Myeloma: Is it Time to Abandon Skeletal Surveys?. Current Oncology. 27:10-11. 2020
- Autologous stem cell transplant in older patients (age ≥ 65) with newly diagnosed multiple myeloma: A systematic review and meta-analysis. Journal of Geriatric Oncology. 11:93-99. 2020
- GERIATRIC ASSESSMENT CHANGES IN OLDER PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA UNDERGOING TREATMENT. Journal of Geriatric Oncology. 10:S73-S74. 2019
- Geriatric Assessment and Frailty Scores Predict Mortality in Myeloma: Systematic Review and Meta-analysis. Clinical Lymphoma, Myeloma and Leukemia. 19:488-496.e6. 2019
- COMPARISON OF FRAILTY SCORES IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA: A REVIEW. The Journal of frailty & aging The Journal of frailty & aging. 8:1-7. 2019
- Development of a Medicare Health Outcomes Survey Deficit-Accumulation Frailty Index and Its Application to Older Patients With Newly Diagnosed Multiple Myeloma. JCO Clinical Cancer Informatics. 2:1-13. 2018
- Novel Treatments for Multiple Myeloma: What Role Do They Have in Older Adults?. Drugs and Aging. 35:289-302. 2018
- Autoimmune HIT due to apheresis catheter heparin flushes for stem cell harvesting before autotransplantation for myeloma. Blood. 130:1679-1682. 2017
- The relationship of CD34+ dosage and platelet recovery following high dose chemotherapy and autologous CD34+ reinfusion in multiple myeloma. Transfusion and Apheresis Science. 56:552-557. 2017
- EspP, an Extracellular Serine Protease from Enterohemorrhagic E. coli, Reduces Coagulation Factor Activities, Reduces Clot Strength, and Promotes Clot Lysis. PLoS ONE. 11:e0149830-e0149830. 2016
- Optimal Manual Exchange Transfusion Protocol for Sickle Cell Disease: A Retrospective Comparison of Two Comprehensive Care Centers in the United Kingdom and Canada. Hemoglobin. 39:310-315. 2015
- Venous thrombosis in inflammatory bowel disease. CMAJ. 187:55-55. 2015
- Crystal Structure of the Passenger Domain of the Escherichia coli Autotransporter EspP. Journal of Molecular Biology. 413:985-1000. 2011
- Mixed Variant Multicentric Castleman Disease Treated With Rituximab: Case Report. Journal of Pediatric Hematology/Oncology. 32:622-622. 2010
-
Quality of
-
chapter
- Haemopoietic Stem Cell Processing and Storage. 455-465. 2017
-
conference paper
- International differences in baseline characteristics and practice patterns in newly diagnosed multiple myeloma (MM) patients undergoing upfront autologous stem cell transplantation. Bone Marrow Transplantation. 44-45. 2022
- Gender disparities in multiple myeloma publications. Journal of Clinical Oncology. 966-969. 2022
- Quality of end-of-life care for patients with multiple myeloma: A 12-year analysis of a population-based cohort.. Journal of Clinical Oncology. 2022
- Part 1 Results of a Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 2021
- Is Symptom Burden Associated with Health Care Utilization: A Longitudinal Population-Based Cohort Study of Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma. Blood. 116-116. 2021
- Lenalidomide Dosing and Outcomes in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database. Blood. 4721-4721. 2021
- Part 1 Results of a dose finding study of Belantamab Mafodotin (GSK2857916) in combination with Pomalidomide (POM) and Dexamethasone (DEX) for the treatment of Relapsed/Refractory Multiple Myeloma. Blood. 1653-1653. 2021
- Cardiovascular events among recipients of hematopoietic stem cell transplantation. European Heart Journal. 2876-2876. 2021
- Extended follow-up safety and efficacy results of Belantamab mafodotin (Belamaf) 1.92 mg/kg or 2.5 mg/kg combined with POM and DEX for the treatment of relapsed/refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia. S162-S162. 2021
- Decision making factors that influence treatment options for an autologous stem cell transplant for older adults (aged 65-75) with Newly Diagnosed Multiple Myeloma: A Mixed Methods.. Blood. 13-13. 2020
- Is tandem ASCT needed in MM patients with high risk cytogenetics in the era of maintenance therapy? Results from the Canadian Myeloma Research Group (CMRG) Database.. Blood. 18-19. 2020
- Sequential use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database.. Blood. 5-7. 2020
- Geriatric Assessment and Frailty Changes in Older Patients with Newly-Diagnosed Multiple Myeloma Undergoing Treatment. Blood. 4774-4774. 2019
- Undertreatment of Older Patients with Newly-Diagnosed Multiple Myeloma: Real World Evidence from a Canadian Registry Cohort. Blood. 268-268. 2019
- Quality of Life Assessment in Older Patients with Newly-Diagnosed Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia. e232-e233. 2019
- The laboratory profile that predicts favorable outcome after Eculizumab therapy in patients with clinical features compatible with atypical hemolytic uremic syndrome. Journal of Thrombosis and Haemostasis. 712-712. 2015
- Characterization of Pulmonary Compliance in Sickle Cell Patients Revealed Wide Variability. Blood. 989-989. 2013
- Attrition rates in Multiple Myeloma: A Canadian Myeloma Research Group
- Causes of Death Among Patients with Multiple Myeloma: A 10 Year Longitudinal Analysis of a Population-Based Cohort in Ontario, Canada
- Duration of Eculizumab therapy for a clinical response in atypical hemolytic uremic syndrome.
- Geriatric assessment and frailty changes in older patients with Newly-Diagnosed Multiple Myeloma.
- Impact of Daratumumab-Containing Regimens in Outcomes of Subsequent Treatments of Relapsed Multiple Myeloma in Real-World Practice from the Canadian Myeloma Research Group Database
- Need for Dynamic Frailty Risk Assessment Among Older Adults with Multiple Myeloma: A Population-Based Cohort Study
- Outcomes of transplant ineligible Myeloma patients using Bortezomib containing regimens vs Lenalidomide and Dexamethasone in the real world: A Report from the Canadian Myeloma Research Group Database
- Quality of life assessment in older patients with Newly Diagnosed Multiple Myeloma.
- Real World Data on Outcomes of Anti-CD38 Antibody Refractory, Including Triple Class Refractory, Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database
- Survival and outcomes of Newly-Diagnosed Multiple Myeloma patients stratified by transplant status diagnosed between 2007-2018: Real-World Analysis from the Canadian Myeloma Research Group
- The impact of marginalization on treatment receipt and overall survival in Newly Diagnosed Multiple Myeloma patients in Ontario: A Population-Based Cohort Study.
- The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A Systematic Review
- Trajectory of symptoms after autologous stem cell transplant among patients with Multiple Myeloma: A Population-Based Study
- Trends in autologous hematopoietic stem cell transplant in older patients with Multiple Myeloma 2000-2017: The Canadian Experience
- Variable Frailty Categorization Among Real-World Patient with Multiple Myeloma: A Prospective Cohort Study (MFRAIL)